tiple insults synergistically acting to induce NAFLD (diet, endotoxemia from gut microbiota, genetic factors). More recently, the definition of NAFLD as the hepatic manifestation of the metabolic syndrome also has been challenged by a new view, which supports a primary role of NAFLD in the pathogenesis of metabolic diseases [2] . We shall discuss recent data on NAFLD pathogenesis, as summarized in figure 1 .
Role of Metabolic Factors
The accumulation of fat in the liver is related to FFA flux from adipose tissue (approximately 60% of the whole FFAs pool), increased de novo lipogenesis (26%) and excess dietary fat (15%) [3] . The circulating pool of FFAs derives from lipolysis in adipocytes [4] , a mechanism under insulin control and favored by insulin resistance (IR), frequently associated with hepatic steatosis [5] . IR might be either a primary defect (see gene polymorphisms), also responsible for hyperglycemia and diabetes, or a phenomenon secondary to liver fat accumulation. Inside the liver, FFA metabolism leads to the production of ceramides, bioactive sphingolipids accumulating in muscle, liver, adipose tissue and pancreatic cells, and plays a crucial role in lipotoxicity and interferes with insulin signaling [6] . The enzymes involved in de novo ceramide synthesis are induced by inflammatory agonists, which further contribute to IR [7] . In healthy conditions, insulin inhibits lipolysis in adipose tissue, whereas in the presence of Graphical representation of mechanisms responsible for liver fat accumulation and liver disease progression in NAFLD. Molecular mechanisms involved in NAFLD development and progression, according to the 'multiple parallel hits' model. IR leads to hepatic steatosis by increasing the overflow of FFA from adipose tissue to the liver (triggering lipolysis). Hepatic TG accumulation, either genetically determined or as effect of IR, is the first step in liver injury; it makes the liver more susceptible to lipotoxicity and oxidative stress (increased TNF-α and IL-6, reduced adiponectin levels). Bacterial overgrowth (SIBO) and impaired gut barrier lead to the delivery of inflammatory components (e.g., LPS) and metabolic factors (e.g., alcohol, choline, acetaldehyde) through the portal blood stream, mediated by upregulated TLRs, determining the accumulation of hepatic lipid droplets and fostering the inflammatory response. Genetic predisposition (mainly PNPLA3, TM6SF2, MERTK and GCKR polymorphisms) may be either the primary defect or act as an additional factor, contributing to hepatic inflammation and lipotoxicity. Hepatic FFA overflow leads to overproduction and systemic delivery of VLDL, increasing lipotoxicity. All these mechanisms determine a vicious cycle responsible for the progression from nonalcoholic fatty liver to NASH, via IR, lipogenesis, inflammation and finally fibrogenesis. IR, lipolysis is continuously activated, resulting in increased FFAs delivery and uptake into the liver [8] . This mechanism creates a vicious circle where IR increases FFA uptake into the liver, which in turn increases IR, particularly in the liver and skeletal muscles [9] . In insulin resistant states, hepatic gluconeogenesis is maintained and leads to hyperglycemia and hyperinsulinemia, mainly in subjects with obesity and/or metabolic syndrome, where these pathways are far more intense, due to increased total fat mass and central adiposity [5] . The whole process is modulated by the diet and by the cytokine response to fat accumulation. Adipocytokines are mainly produced by inflammatory cells, infiltrating the adipose tissue, and promote IR in fat tissues, as well as hepatocellular damage, inflammation, fibrosis and progressive disease in the liver. Adiponectin is one of the major products of adipocytes and exerts anti-inflammatory effects, specifically in the liver; its levels are inversely associated with necroinflammation and steatosis in NAFLD [10] . Low adiponectin levels may also predispose patients to advanced liver disease, as part of the inflammatory milieu associated with metabolic disorders [11] , but a direct effect of adiponectin and other cytokines [12] in the progression from pure fatty liver to NASH has never been fully confirmed.
Diet is the second actor in the complex interplay leading to NAFLD. There is strong evidence that dietary factors are involved in the pathogenesis of hepatic steatosis ( table 1 ) . In general, the detrimental effects of high-fat diets are well documented, both in the short and in the long term [13, 14] , but not all fat are alike, and monounsaturated and polyunsaturated fats may also be protective, provided that total fat intake is maintained within a reasonable percent of total calories. A high-fat diet induces ceramide production, further increasing hepatic IR [15] . The role of dietary carbohydrates is less predictable, but an excessive intake of high glycemic index foods may promote liver fat by turning dietary carbohydrates into fatty acids, that is, by inducing de novo hepatic lipogenesis and decreasing lipid oxidation. On the contrary, a low-energy, low-CHO diet is reported to clear liver fat in a few days [16] . This opens the question of the importance of refined carbohydrates in the pathogenesis of liver fat, including the specific effect of high-fructose corn syrup, extensively dealt with in several review articles [17, 18] .
Although specific dietary components may either increase or reduce the risk of steatosis, the amount of calories and weight loss remain pivotal in the pathogenesis and treatment of NAFLD, as well as in disease progression [19] . The importance of the diet is extensively supported by the epidemiological evidence and further emphasized by the results of clinical trials pointing to weight loss as the primary intervention for NAFLD, also decreasing the risk of NAFLD progression [20] .
Role of Gut Microbiota
Preclinical and clinical studies support a role of gut microbiota in NAFLD pathogenesis, mainly through predisposition to obesity, causing IR and hepatic inflammation. The interaction between the gut flora and the liver is favored by its anatomical link; the liver receives 70% of its blood supply from the intestine through the portal vein, is exposed to gut-derived toxic factors and represents the first line of defense against gut-derived antigens. Gut microflora may stimulate hepatic fat deposition and foster NASH through several mechanisms depicted in figure 1 .
Microbiota and Calorie Balance
The intestinal microbiota may increase intrahepatic fat via altered appetite signaling, increased energy extraction from nutrients, altered expression of genes involved in de novo lipogenesis, β-oxidation or lipid storage or via inflammation-driven steatosis [21, 22] . Obesity-associated gut microbiota extracts more energy from the diet because it is able to process otherwise indigestible polysaccharides into short-chain fatty acids (SCFAs).
Turnbaugh et al. [23] provided the first evidence for a role of gut microbiota in obesity: the transplantation of gut microbiota from obese to germ-free mice led to higher fat gain other than microbiota from lean donors. SCFAs are elevated in the gut of obese patients; the microbiota from obese individuals increased the production of SCFAs and energy yield compared with that of lean individuals. Bacteroidetes (e.g., Prevotella ) produce more SCFAs and both obese and NASH patients have increased Bacteroidetes counts and lower counts of Firmicutes [24] , also in the pediatric population [25] . Mouzaki et al. [22] found lower counts of Bacteroidetes in NASH patients compared with patients with simple steatosis and healthy controls, but most data require confirmation [26] .
Gut microbiota is also dependent on dietary changes (especially changes in long-term food habits), and Firmicutes are more efficient in calorie extraction. On the other hand, Proteobacteria are the main bacteria expressing endotoxins; they activate hepatic stellate cells (HSCs) and promote liver fibrogenesis in the course of liver damage [27] .
Although inter-individual differences in the intestinal microbiome seem to modulate the metabolic and hepatic consequences of high-fat diet, no definite conclusion can be derived for a potential causative role of particular phyla and genus in NAFLD/NASH development. The direct effect of the microbiota on dietary energy absorption is just one factor in the risk for NAFLD and NASH, and other mechanisms are involved, considering that not all obese individuals develop NASH and increased caloric intake does not fully explain NASH pathogenesis [28] .
Gut Permeability and Immune Function
Gut microbiota protects against pathogens, participates in the maturation and integrity of the gut barrier and promotes immunity homeostasis. This depends on specific pattern recognition receptors, including toll-like receptors (TLRs) that recognize microbial molecules called 'pathogen-associated molecular patterns' (PAMPs), working as immune sensors. The most studied PAMP is the lipopolysaccharide (LPS), a component of the cell membrane of gram-negative bacteria. LPS activates TLR-4 that is present in Kupffer cells, thereby triggering an essential inflammatory cascade and inducing the transcription of numerous pro-inflammatory genes such as TNF-α and IL-1b . The cross-talk between host and bacteria interacts with innate immunity, leads to loss of junctions in the small intestinal epithelium facilitating the flow of bacterial products into the portal vein system and to the liver. Here, they activate inflammasome pathways resulting in a cascade of proinflammatory cytokines, which ultimately leads to liver injury and progression of NAFLD to fibrosis.
Miele et al. [29] provided the first evidence of an increased intestinal permeability (leaky gut) and tight junction alterations in biopsy-proven NAFLD. Both disruption of the intestinal barrier and small intestinal bacterial overgrowth correlate with the severity of steatosis, and inflammation is associated with hepatic fibrogenesis [30] . Endotoxin levels are increased in adults and children with NASH [31, 32] , in association with early fibrosis. However, endotoxemia is absent in the majority of NASH patients; it may contribute to disease progression in some NASH cases, but it is not a necessary component.
Dietary Choline Metabolism
Choline is an essential nutrient and an important phospholipid component of cell membrane. Choline plays a key role in fat metabolism and very low-density lipoprotein (VLDL) assembly in the liver, and low-choline diets are associated with health problems, including hepatic steatosis [33] . Enzymes produced by the gut microbiota catalyze the conversion of dietary choline into toxic methylamines, which potentially induce NASH when absorbed by the liver [34] . A single nucleotide polymorphism (SNP) affecting choline metabolism predicts the severity of steatosis on a choline-deficient diet [35] .
Bile Acid Metabolism
In human physiology, bile acids are recognized as important cell signaling molecules that activate multiple pathways regulating lipid metabolism, carbohydrate metabolism and inflammatory response. They have a strong antimicrobial activity, acting on bacterial cell membrane [36] .
Diets high in saturated fats, by inducing changes in host bile acid composition, may result in dysbiosis. In turn, gut microbiota is able to modulate bile acid metabolism, especially through binding and activation of the nuclear farnesoid-X receptor (FXR) [37] , resulting in inhibition of gluconeogenesis and glycogenolysis in the liver (improving glucose metabolism) and increased insulin sensitivity in adipose and skeletal muscle. In a series of experiments on high fat induced NAFLD in mice, the disruption of microbiome by antibiotics altered bile acid composition, inhibited intestinal FXR signaling and led to a reduction in hepatic TG accumulation [38] .
Endogenous Ethanol Production
Intestinal microflora produces a number of potentially hepatotoxic compounds such as ethanol, phenols and ammonia that are delivered into the liver where they activate Kupffer cells to produce nitric oxide and cytokines [39] .
Occasional drinking might result in positive serum alcohol in adults with NAFLD, but serum alcohol concentrations are also elevated in pediatric NASH [24] , where the possible contribution of alcoholic drinks, fruit or aspartame on serum alcohol is excluded. The microbiome composition of NASH patients and obese individuals is similar except for Escherichia genus, which exhibits a mixed-acid fermentation pathway and produce high amounts of ethanol. A high-fat diet is possibly involved in the abundance of alcohol-producing Escherichia in NAFLD [25] , possibly enhanced by an insulin-dependent impairment of alcohol dehydrogenase activity in liver tissue [40] .
Notably, increased ethanol production by the microbiota, through its oxidation to acetate and acetaldehyde, provides substrates for fatty acids synthesis and the production of reactive oxygen species. Increased gut mucosal permeability would thus induce TG accumulation in the liver and hepatic oxidative stress putting the individuals at risk for NASH. Therefore, ethanol metabolism qualifies for both steps of the '2-hits' hypothesis.
Role of Genes
Obesity, IR, inflammation and lipotoxicity have a direct role on liver disease development and progression, but both the occurrence and severity of NAFLD cannot be solely attributed to the above-mentioned determinants. The genetic background may represent the soil where environmental factors play their pathological effect, influencing the progression across the entire spectrum of liver disease.
Recent epidemiological, familial and twin studies have described the complex interplay between genetics and environment, unraveling a high heritability for the occurrence of liver disease [41, 42] . Two large epidemiological studies had already outlined an increasing gradient of fatty liver in relation to ethnicity after adjusting for confounders (African Americans < Caucasians < Hispanics < Asian-Indians) [43, 44] .
In the past few years, advances in genotyping technology have largely contributed to the understanding of the genetics of NAFLD; data arising from genome-wide association studies (GWAS) have convincingly associated a few SNPs in the genes involved in lipid metabolism, insulin signaling, oxidative stress and fibrogenesis with the risk for NAFLD occurrence and progression ( table 2 ) . The best-characterized polymorphism is the patatin-like phospholipase domain containing 3 (PNPLA3)/adiponutrin, rs738409 CG , which has been associated with magnetic resonance-assessed steatosis [45] and has been validated as risk factor for NASH severity and progression [46] in multiple cohorts and ethnicities [47, 48] . In particular, the PNPLA3 genotype has been acknowledged as a major genetic determinant of liver TG accumulation and increased liver enzymes [45] .
The PNPLA3 gene, located on the long arm of chromosome 22, encodes a transmembrane polypeptides chain, highly expressed in hepatocytes and adipose tissue, with a triacylglycerol lipase activity that mediates triacylglycerol hydrolysis in adipocytes; as such, it is properly involved in the balance of energy usage/storage in adipocytes. The SNP rs738409 CG , encoding an isoleucine-tomethionine substitution, is responsible for a loss of function that impairs the enzymatic activity, leading to defective lipid catabolism, impaired secretion of VLDLs by hepatocytes and enhanced de novo lipogenesis.
Valenti et al. [48] confirmed that the adiponutrin rs738409 genotype influences both the presence of NASH and the severity of fibrosis, independent of the degree of obesity and the presence of diabetes. In these patients, steatosis should no longer be considered a 'first hit' in the onset, and progression of liver damage and PNPLA3 might be involved in pathogenic mechanisms of NASH and fibrosis, independent of its effects on TG accumulation. The effects on lipid metabolism may also explain extrahepatic comorbidities, namely carotid atherosclerosis and chronic kidney disease; PNPLA3 gene variants, by regulating apoptotic activity, might exert a pathogenic effect on vascular endothelium thus modulating the atherosclerotic process [49] . Adiponutrin expression might influence liver fat independently of BMI, dyslipidemia and IR, exerting a larger effect in patients without metabolic syndrome [50] . Interestingly, a population-based study showed an association between PNPLA3 variants and a more favorable metabolic profile [51] .
Another gene, the transmembrane 6 superfamily 2 human gene ( TM6SF2 ) has been reported as disease modifier, interfering with lipoprotein secretion and assisting in risk stratification for liver-related morbidity [46] . TM6SF2 encodes for a protein regulating hepatic TG secretion. The E167K aminoacidic substitution is responsible for a loss of function causing a reduced secretion of VLDLs [52] . Notably, the carriers of the TM6SF2 E167K variant, probably as a result of lower circulating lipids, have a low risk of atherosclerosis and myocardial infarction [52] , in spite of a high risk of progressive NASH.
More recently, GWAS identified other SNPs associated with fatty liver in European patients. Among these variants, the glucokinase regulatory ( GCKR ) protein gene 8 has been confirmed as linked with steatosis, identified either by ultrasonography or magnetic resonance or computed tomography, in pediatric patients, obese subjects, and in different ethnicity populations [46, 53, 54] . In agreement with previous findings [46, 53] , Petta et al. [54] confirmed that homozygosity for the T allele of GCKR is associated with higher levels of serum TGs and ALT. The gene product, the GCKR protein, interferes with glucose and lipid homeostasis by regulating glucose storage/disposal and by providing substrates for de novo lipogenesis [55] . As for other genes variants, the GCKR mutation not only represents a risk factor for the development of fatty liver, but it is also associated with progression toward more advanced histological damage [53] , after correction for PNPLA3 genotype [54] . Importantly, the severity of liver fibrosis showed a stepwise increase from carriers of only one risk allele compared to carriers of 2 risk alleles [54] , also enhanced by a low grade chronic inflammation.
In a very recent study on more than 600 biopsied patients with suspected NASH, the presence of clinically significant fibrosis (F2-F4) was also associated with the absence of MERTK AA genotype, after correction for confounders and for both PNPLA3 and TM6SF2 gene variants [56] . MERTK is a receptor of the tumor-associated macrophage family, involved in efferocytosis (the process by which apoptotic cells are filtered out by phagocytes). In NAFLD patients, MERTK is mostly expressed in macrophages and HSCs, and a significantly lower hepatic expression of MERTK in subjects carrying the AA genotype might protect from fibrosis progression.
Other gene polymorphisms are less systematically associated with NAFLD. Apolipoprotein C3 gene variants have been shown to increase the risk of NAFLD in Indians [57] , associated with lower plasma TG clearance. Even in less detail, variants in or near protein phosphatase 1 regulatory subunit 3B ( PPP1R3B ), encoding for a protein regulating glycogen breakdown [58] ; and variants in or near neurocan ( NCAN ), encoding for an adhesion molecule involved in different multisystemic diseases; and in or near lysophospholipase-like 1 ( LYPLAL1 ), have been associated to hepatic steatosis [46] . Variants in or near NCAN and PPP1R3B are associated with altered circulating lipid levels, whereas LYPLAL1 does not; variants near NCAN and PPP1R3B also affect glycemic traits. These results provide evidence that steatosis may stem from different metabolic pathways. Variants in or near NCAN and LYPLAL1 , not PPP1R3B , also present an association with lobular inflammation or fibrosis at histology. NAFLD is the hepatic consequence of a systemic metabolic imbalance; for this reason, the combination of genes and metabolic factors should always be considered in the pathogenesis of NAFLD, the severity of its progression, as well as the severity of extrahepatic comorbidities and in particular cardiovascular disease.
Conclusion
NAFLD is the most common chronic liver disease and has rapidly become an important cause of liver failure and hepatocellular carcinoma. Even though it is strongly associated with obesity and metabolic syndrome, a small but significant proportion of patients develop NAFLD despite the absence of a pathological metabolic profile. Thus, the pathogenesis of NAFLD appears to be multifactorial, involving behavioral, internal and genetic factors. The complex interplay of all these factors involves liver interactions with other organs and tissues, especially the hormonal milieu generated by the counterbalancing actions of insulin and glucagon, as well as the activity of adipose tissue as an endocrine organ and the so-called 'gut-liver axis'.
Any attempt to modify the occurrence and the progression of NAFLD should start from dietary habits and physical activity, limiting calorie intake as well as increasing energy expenditure, as the most effective way to prevent and/or reduce liver fat accumulation. We need to develop strategies to help subjects favor healthy habits; in the present culture of biomedicine, it is however very challenging to make NAFLD subjects aware that they must become the masters of their fate, and less confidently relay on pharmacologic intervention.
The possibility that the crosstalk of the intestinal microbiota with the host immune system may modulate inflammation, IR and intestinal permeability has opened new areas of research. The expanding fields of metagenomics, metatranscriptomics and metabolomics, which examine the genomic capacity, gene expression profiles and small metabolites of microbial communities, respectively, will be key tools for advancing the science in this field. A better knowledge of the effects of foods and nutrients in relation to gene polymorphisms and the microbial functional pathways most closely associated with NAFLD and NASH is expected to provide new targets for future diagnostic testing and treatment.
